Liberals protested in California against U.S. President Donald Trump's crackdown on illegal immigrants. Thousands gathered at Los Angeles City Hall on Sunday, February 2, to rally against the mass ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

Merck MRK-0.87%decrease; red down pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech that spans ...

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...